• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

辽宁成大公司生产的纯化Vero细胞狂犬病疫苗(PVRV)在50岁及以上中国成年人中按照萨格勒布2-1-1或5剂埃森方案接种后的免疫原性和安全性。

Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above.

作者信息

Wang Jing, Luo FengJi, Feng ZiJian, Li Li, Bai YunHua, Ai Xing, Ma JianXin, Zhang Zheng, Shi NianMin

机构信息

a ChaoYang Center for Disease Prevention and Control , Beijing , China.

b China Center for Disease Prevention and Control ; Beijing , China.

出版信息

Hum Vaccin Immunother. 2017 Jan 2;13(1):144-150. doi: 10.1080/21645515.2016.1230260.

DOI:10.1080/21645515.2016.1230260
PMID:28045585
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5287299/
Abstract

BACKGROUND

Two kinds of regimens (2-1-1 and 1-1-1-1-1) can be selected after Zagreb regimen(2-1-1)of PVRV was officially approved in Beijing in January 2015. Up to now, the subjects for most studies about the comparison between Zagreb and Essen regimen are under 50 y old, rarely at and above. Aging of the immune system may result in decreasing efficacy of vaccination, especially for adults aged above 65-70 y. This study compared the safety and immunogenicity of the Zagreb and Essen regimen in Chinese adults aged 50 and above with the goal to provide a supplemental data for this age group.

METHODS

A total of 114 cases were divided into 2 groups randomly, received PVRV under the Zagreb and Essen regimens respectively. Serum samples were collected at D0, D7, D14, D42, D180 and D365 to determine the rabies serum neutralizing antibody by rapid fluorescent focus inhibition test (RFFIT). Safety analyses were made by comparing the AEs in day-3, day-7, and day-(7 + 21) in Zagreb or day-(7 + 28) in Essen by gender and age cohorts.

RESULTS

617 blood samples were obtained. Two groups showed similar immunogenicity, the neutralizing antibody titer of all subjects at D14 and D42 showed >0.5 IU/ml. Under the same regimen, Subjects ≥65 y had lower GMC than those who <65 years from D7 to D365 within 2 groups. This difference was significantly shown on D7, D14, D180 in Zagreb group, and on D180 in Essen group (t = 2.38, p = 0.02; t = 3.78, p < 0.001; t = 2.30, p = 0.03; t = 4.42, p < 0.001). Subjects<65 years had higher seroconversion rate compared to ≥65 y on D7, D180 and D365 in both 2 groups, this difference was also significantly shown on D180, D365 in Zagreb group and on D180 in Essen group (χ = 20.66, p < 0.001; χ = 6.56, p = 0.02; χ = 10.96, p = 0.002). Two regimens all showed favorable performances with mildly or common adverse events (AEs). The incidence of local AEs after 3 d in Essen group was higher than Zagreb group (χ = 9.69, p = 0.002). The most common local AE was pain, the incidences (8.8%) in Zagreb group was higher than Essen group (8.4%, χ = 5.12, p = 0.02). All AEs for Zagreb group and 52.3% of AEs for Essen group occurred during the first 72 hours. During the first 72 hours, subjects aged <65 in Zagreb group (16.26%) had higher incidences of AEs than Essen group (8.57%, χ = 4.54, p = 0.03), males in Zagreb group (16.05%) had higher incidence of AEs than Essen group (5.71%, χ = 5.34, p = 0.02). The incidences of AEs close in during the first 7 d.

CONCLUSION

The Zagreb and Essen regimens demonstrated the similar safety and efficacy of PVRV in Chinese adults aged 50 and above. People ≥65 y showed reduced immune response to both regimens. More AEs for the Zagreb regimen were observed within the first 72 hours, especially for male and people < 65 y.

摘要

背景

2015年1月,北京正式批准采用萨格勒布方案(2-1-1)后,可选择两种方案(2-1-1和1-1-1-1-1)。到目前为止,大多数关于萨格勒布方案和埃森方案比较的研究对象年龄在50岁以下,很少有50岁及以上的。免疫系统衰老可能导致疫苗接种效果下降,尤其是65 - 70岁及以上的成年人。本研究比较了萨格勒布方案和埃森方案在中国50岁及以上成年人中的安全性和免疫原性,旨在为该年龄组提供补充数据。

方法

共114例患者随机分为2组,分别接受萨格勒布方案和埃森方案的人用狂犬病疫苗(PVRV)接种。在第0、7、14、42、180和365天采集血清样本,通过快速荧光灶抑制试验(RFFIT)检测狂犬病血清中和抗体。通过比较萨格勒布方案第3、7天和第(7 + 21)天或埃森方案第(7 + 28)天按性别和年龄队列划分的不良事件(AE)进行安全性分析。

结果

共获得617份血样。两组免疫原性相似,所有受试者在第14天和第42天的中和抗体滴度均>0.5 IU/ml。在相同方案下,两组中≥65岁的受试者在第7天至第365天的几何平均浓度(GMC)低于<65岁的受试者。这种差异在萨格勒布组的第7、14、180天以及埃森组的第180天有显著表现(t = 2.38,p = 0.02;t = 3.78,p < 0.001;t = 2.30,p = 0.03;t = 4.42,p < 0.001)。在第7、180和365天,两组中<65岁的受试者血清转化率均高于≥65岁的受试者,这种差异在萨格勒布组的第180、365天以及埃森组的第180天也有显著表现(χ = 20.66,p < 0.001;χ = 6.56,p = 0.02;χ = 10.96,p = 0.002)。两种方案的不良事件均表现为轻度或常见。埃森组接种3天后局部AE的发生率高于萨格勒布组(χ = 9.69,p = 0.002)。最常见的局部AE是疼痛,萨格勒布组的发生率(8.8%)高于埃森组(8.4%,χ = 5.12,p = 0.02)。萨格勒布组的所有AE和埃森组52.3%的AE发生在最初72小时内。在最初72小时内,萨格勒布组<65岁的受试者AE发生率(16.26%)高于埃森组(8.57%,χ = 4.54,p = 0.03),萨格勒布组男性AE发生率(16.05%)高于埃森组(5.71%,χ = 5.34,p = 0.02)。第1周内AE发生率相近。

结论

萨格勒布方案和埃森方案在50岁及以上中国成年人中显示出相似的人用狂犬病疫苗安全性和有效性。≥65岁的人群对两种方案的免疫反应均降低。萨格勒布方案在最初72小时内观察到更多AE,尤其是男性和<65岁的人群。

相似文献

1
Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above.辽宁成大公司生产的纯化Vero细胞狂犬病疫苗(PVRV)在50岁及以上中国成年人中按照萨格勒布2-1-1或5剂埃森方案接种后的免疫原性和安全性。
Hum Vaccin Immunother. 2017 Jan 2;13(1):144-150. doi: 10.1080/21645515.2016.1230260.
2
A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.一项随机、开放性标签研究,旨在证明在中国人中,采用萨格勒布方案(2-1-1)接种纯化鸡胚细胞狂犬病疫苗与埃森方案相比具有非劣效性。
Hum Vaccin Immunother. 2014;10(10):2805-12. doi: 10.4161/21645515.2014.972773.
3
Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.在6至17岁中国儿童及50岁以上成年人中,采用萨格勒布2-1-1或5剂埃森方案的纯化鸡胚细胞狂犬病疫苗的免疫原性和安全性:一项随机开放标签研究。
Hum Vaccin Immunother. 2015;11(2):435-42. doi: 10.4161/21645515.2014.994460.
4
Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial.在健康的中国受试者中,根据萨格勒布 2-1-1 或 5 剂埃森方案,使用纯化vero 细胞狂犬病疫苗的免疫原性和安全性:一项随机、双盲、阳性对照的 3 期临床试验。
Hum Vaccin Immunother. 2021 Feb 1;17(2):351-357. doi: 10.1080/21645515.2020.1778408. Epub 2020 Aug 12.
5
Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV).一种新型经色谱纯化的Vero细胞狂犬病疫苗(CPRV)在成人中的免疫原性和安全性:一项与纯化Vero细胞狂犬病疫苗(PVRV)对比的随机双盲试验。
Biologicals. 1998 Dec;26(4):299-308. doi: 10.1006/biol.1998.0156.
6
Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.在暴露后人群中,采用萨格勒布方案或埃森方案接种纯化 vero 细胞培养狂犬病疫苗(Speeda)后的免疫原性、安全性及抗体持久性。
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-8. doi: 10.1080/21645515.2017.1279770. Epub 2017 Jan 25.
7
Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China.中国II级暴露患者中使用萨格勒布和埃森方案的纯化鸡胚细胞疫苗的安全性和免疫原性比较。
Hum Vaccin Immunother. 2014;10(6):1645-9. doi: 10.4161/hv.28420. Epub 2014 Mar 14.
8
Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen).根据两种不同模拟暴露后肌肉注射方案(萨格勒布方案与埃森方案)接种纯化鸡胚细胞狂犬病疫苗(PCECV)的免疫原性和安全性的比较研究。
Hum Vaccin Immunother. 2015;11(2):428-34. doi: 10.4161/21645515.2014.995059.
9
The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen.中国2-1-1免疫程序下纯化Vero细胞狂犬病疫苗(PVRV)接种的免疫原性和安全性。
Hum Vaccin. 2011 Feb;7(2):220-4. doi: 10.4161/hv.7.2.14003. Epub 2011 Feb 1.
10
A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.在中国,健康儿童和成年人按照接触后程序接种时,新一代、无血清、高度纯化的 Vero 细胞狂犬病疫苗具有良好的安全性,其免疫原性与对照疫苗 Verorab®相当。
Vaccine. 2013 Dec 5;31(50):5940-7. doi: 10.1016/j.vaccine.2013.10.043. Epub 2013 Oct 19.

引用本文的文献

1
A phase 3 clinical trial on the immunogenicity and safety of booster vaccination after Zagreb or Essen regimens.一项关于萨格勒布或埃森方案后加强疫苗接种的免疫原性和安全性的3期临床试验。
Sci Rep. 2025 Feb 27;15(1):7079. doi: 10.1038/s41598-025-88361-1.
2
Safety, immunogenicity and immune-persistence of a lyophilized human rabies vaccine (Vero cells) under Zagreb and Essen regimens: a randomized, open-label, controlled phase III clinical trial in healthy participants aged 10-60 years in China.在萨格勒布和埃森方案下冻干人用狂犬病疫苗(Vero 细胞)的安全性、免疫原性和免疫持久性:在中国健康 10-60 岁人群中进行的一项随机、开放标签、对照的 III 期临床试验。
Front Immunol. 2024 Nov 7;15:1444686. doi: 10.3389/fimmu.2024.1444686. eCollection 2024.
3
Safety and immunogenicity of freeze-dried human rabies vaccines: A phase 3 clinical trial of Zagreb and Essen regimes.冻干人用狂犬病疫苗的安全性和免疫原性:萨格勒布和埃森方案的 3 期临床试验。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2426289. doi: 10.1080/21645515.2024.2426289. Epub 2024 Nov 13.
4
A Randomized, Double-Blind, Controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of a Lyophilized Human Rabies Vaccine (Vero Cells) in Healthy Participants Aged 10-60 Years Following Essen and Zagreb Vaccination Procedures.一项随机、双盲、对照的III期临床试验,旨在评估冻干人用狂犬病疫苗(Vero细胞)在10至60岁健康参与者中按照埃森和萨格勒布接种程序接种后的免疫原性和安全性。
Vaccines (Basel). 2023 Aug 1;11(8):1311. doi: 10.3390/vaccines11081311.
5
Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis.人二倍体细胞疫苗(HDCV)与纯化vero 细胞疫苗(PVRV)和纯化鸡胚细胞疫苗(PCECV)在暴露后预防中的免疫原性和安全性比较:系统评价和荟萃分析。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2027714. doi: 10.1080/21645515.2022.2027714. Epub 2022 Feb 22.
6
Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: A post-marketing, parallel control clinical trial.在接触后人群中按萨格勒布和埃森方案接种冻干纯化vero 细胞狂犬病疫苗的安全性、免疫原性:上市后、平行对照临床试验。
Hum Vaccin Immunother. 2021 Aug 3;17(8):2547-2553. doi: 10.1080/21645515.2021.1880200. Epub 2021 Feb 25.
7
Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial.在健康的中国受试者中,根据萨格勒布 2-1-1 或 5 剂埃森方案,使用纯化vero 细胞狂犬病疫苗的免疫原性和安全性:一项随机、双盲、阳性对照的 3 期临床试验。
Hum Vaccin Immunother. 2021 Feb 1;17(2):351-357. doi: 10.1080/21645515.2020.1778408. Epub 2020 Aug 12.

本文引用的文献

1
Worldwide rabies deaths prevention--A focus on the current inadequacies in postexposure prophylaxis of animal bite victims.全球狂犬病死亡预防——关注动物咬伤受害者暴露后预防措施当前存在的不足
Vaccine. 2016 Jan 4;34(2):187-189. doi: 10.1016/j.vaccine.2015.11.036. Epub 2015 Nov 25.
2
Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.在6至17岁中国儿童及50岁以上成年人中,采用萨格勒布2-1-1或5剂埃森方案的纯化鸡胚细胞狂犬病疫苗的免疫原性和安全性:一项随机开放标签研究。
Hum Vaccin Immunother. 2015;11(2):435-42. doi: 10.4161/21645515.2014.994460.
3
A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.一项随机、开放性标签研究,旨在证明在中国人中,采用萨格勒布方案(2-1-1)接种纯化鸡胚细胞狂犬病疫苗与埃森方案相比具有非劣效性。
Hum Vaccin Immunother. 2014;10(10):2805-12. doi: 10.4161/21645515.2014.972773.
4
Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China.中国II级暴露患者中使用萨格勒布和埃森方案的纯化鸡胚细胞疫苗的安全性和免疫原性比较。
Hum Vaccin Immunother. 2014;10(6):1645-9. doi: 10.4161/hv.28420. Epub 2014 Mar 14.
5
Determinants of delay in initiating post-exposure prophylaxis for rabies prevention among animal bite cases: hospital based study.动物咬伤后延迟启动狂犬病预防的影响因素:基于医院的研究。
Vaccine. 2013 Dec 17;32(1):74-7. doi: 10.1016/j.vaccine.2013.10.067. Epub 2013 Nov 1.
6
A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.在中国,健康儿童和成年人按照接触后程序接种时,新一代、无血清、高度纯化的 Vero 细胞狂犬病疫苗具有良好的安全性,其免疫原性与对照疫苗 Verorab®相当。
Vaccine. 2013 Dec 5;31(50):5940-7. doi: 10.1016/j.vaccine.2013.10.043. Epub 2013 Oct 19.
7
WHO Expert Consultation on Rabies. Second report.世界卫生组织狂犬病专家磋商会。第二次报告。
World Health Organ Tech Rep Ser. 2013(982):1-139, back cover.
8
Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers.提高狂犬病预防的经济性:在健康志愿者中使用2-1肌内注射方案的初步研究的免疫原性和安全性结果
Hum Vaccin Immunother. 2014;10(1):114-9. doi: 10.4161/hv.26264. Epub 2013 Sep 5.
9
Immunosenescence and novel vaccination strategies for the elderly.免疫衰老与老年人新型疫苗接种策略。
Front Immunol. 2013 Jun 28;4:171. doi: 10.3389/fimmu.2013.00171. Print 2013.
10
Senescent remodeling of the immune system and its contribution to the predisposition of the elderly to infections.免疫系统的衰老重塑及其对老年人易感染的倾向的贡献。
Chin Med J (Engl). 2012 Sep;125(18):3325-31.